Book ChapterDOI
Search, Identification, and Design of Effective Antiviral Drugs Against Pandemic Human Coronaviruses.
Tianguang Huang,Lin Sun,Dongwei Kang,Vasanthanathan Poongavanam,Xinyong Liu,Peng Zhan,Luis Menéndez-Arias +6 more
TLDR
A detailed summary of the current situation in the development of drugs directed against pandemic human coronaviruses can be found in this article, where the authors provide a detailed review of the antiviral armamentarium.Abstract:
Recent coronavirus outbreaks of SARS-CoV-1 (2002-2003), MERS-CoV (since 2012), and SARS-CoV-2 (since the end of 2019) are examples of how viruses can damage health care and generate havoc all over the world. Coronavirus can spread quickly from person to person causing high morbidity and mortality. Unfortunately, the antiviral armamentarium is insufficient to fight these infections. In this chapter, we provide a detailed summary of the current situation in the development of drugs directed against pandemic human coronaviruses. Apart from the recently licensed remdesivir, other antiviral agents discussed in this review include molecules targeting viral components (e.g., RNA polymerase inhibitors, entry inhibitors, or protease inhibitors), compounds interfering with virus-host interactions, and drugs identified in large screening assays, effective against coronavirus replication, but with an uncertain mechanism of action.read more
Citations
More filters
Journal ArticleDOI
Curing Cats with Feline Infectious Peritonitis with an Oral Multi-Component Drug Containing GS-441524.
Daniela Krentz,Katharina Zenger,Martin Alberer,Sandra Felten,Michèle Bergmann,Roswitha Dorsch,Kaspar Matiasek,Laura Kolberg,Regina Hofmann-Lehmann,Marina L. Meli,Andrea M. Spiri,Jeannie Horak,Saskia Weber,Cora M Holicki,Martin H. Groschup,Yury Zablotski,Eveline Lescrinier,Berthold Koletzko,Ulrich von Both,Katrin Hartmann +19 more
TL;DR: In this paper, the authors evaluated efficacy and toxicity of the multi-component drug Xraphconn® in vitro and as oral treatment in cats with spontaneous FIP by examining survival rate, development of clinical and laboratory parameters, viral loads, anti-FCoV antibodies, and adverse effects.
Journal ArticleDOI
Discovery and mechanism of action of Thonzonium bromide from an FDA-approved drug library with potent and broad-spectrum inhibitory activity against main proteases of human coronaviruses
Ruyu Wang,Guanglei Zhai,Guanghao Zhu,Mengge Wang,Xiaoyi Gong,Weidong Zhang,Guang-Bo Ge,Hongzhuan Chen,Lili Chen +8 more
TL;DR: Wang et al. as discussed by the authors identified Thonzonium bromide as an inhibitor of SARS-CoV-2 3CLpro with an IC50 value of 2.04 ± 0.25 μM by fluorescence resonance energy transfer (FRET)-based enzymatic inhibition assay from the FDA-approved drug library.
Journal ArticleDOI
Chemical construction and anti-HCoV-OC43 evaluation of novel 10,12-disubstituted aloperine derivatives as dual cofactor inhibitors of TMPRSS2 and SR-B1
Yulong Shi,Mengyuan Wu,Xin Zhang,Runze Meng,Kun Wang,Yan Bing Wang,Yuheng Mei,Ying-Hong Li,Rong-Mei Gao,Yu-Huan Li,Hongbin Deng,Jiandong Jiang,Yanxiang Wang,Dan-Qing Song +13 more
TL;DR: In this paper , a new 10,12-disubstituted aloperine derivatives were subtly constructed through a selective oxidation on the 10-α-C-H induced by sulfonyl and a nucleophilic substitution with the stereoselectivity and scalability.
Journal ArticleDOI
Preventive and therapeutic benefits of nelfinavir in rhesus macaques and human beings infected with SARS-CoV-2
Zhijian Xu,Danrong Shi,Jian-Bao Han,Yun Ling,Xiangrui Jiang,Xiangyun Lu,Chuan-Rong Li,Likun Gong,Guang-Bo Ge,Yani Zhang,Yinliang Zang,Tian-Zhang Song,Xiao-Li Feng,Ren Tian,Jia Ji,Miaojin Zhu,Nanping Wu,Chunhui Wu,Zhen Wang,Yechun Xu,Cheng Peng,Min Zheng,Junling Yang,Feifei Du,Jun-Zhu Wu,Peipei Wang,Jingshan Shen,Jianliang Zhang,Yongchui Zheng,Hangping Yao,Wei Zhou +30 more
TL;DR: In this paper , the authors reported that nelfinavir, an FDA-approved drug for the treatment of HIV infection, is effective against SARS-CoV-2 and COVID-19.
References
More filters
Journal ArticleDOI
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Peng Zhou,Xing-Lou Yang,Xian Guang Wang,Ben Hu,Lei Zhang,Wei Zhang,Hao Rui Si,Yan Zhu,Bei Li,Chao Lin Huang,Hui-Dong Chen,Jing Chen,Yun Luo,Hua Guo,Ren Di Jiang,Meiqin Liu,Ying Chen,Xu Rui Shen,Xi Wang,Xiao Shuang Zheng,Kai Zhao,Quanjiao Chen,Fei Deng,Lin Lin Liu,Bing Yan,Fa Xian Zhan,Yan-Yi Wang,Gengfu Xiao,Zhengli Shi +28 more
TL;DR: Identification and characterization of a new coronavirus (2019-nCoV), which caused an epidemic of acute respiratory syndrome in humans in Wuhan, China, and it is shown that this virus belongs to the species of SARSr-CoV, indicates that the virus is related to a bat coronav virus.
Journal ArticleDOI
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.
Roujian Lu,Xiang Zhao,Juan Li,Peihua Niu,Bo Yang,Honglong Wu,Wenling Wang,Hao Song,Baoying Huang,Na Zhu,Yuhai Bi,Xuejun Ma,Faxian Zhan,Liang Wang,Tao Hu,Hong Zhou,Zhenhong Hu,Weimin Zhou,Li Zhao,Jing Chen,Yao Meng,Ji Wang,Yang Lin,Jianying Yuan,Zhihao Xie,Jinmin Ma,William J. Liu,Dayan Wang,Wenbo Xu,Edward C. Holmes,George F. Gao,George F. Gao,Guizhen Wu,Weijun Chen,Weifeng Shi,Wenjie Tan,Wenjie Tan +36 more
TL;DR: The phylogenetic analysis suggests that bats might be the original host of this virus, an animal sold at the seafood market in Wuhan might represent an intermediate host facilitating the emergence of the virus in humans.
Journal ArticleDOI
COVID-19: consider cytokine storm syndromes and immunosuppression
Puja Mehta,Daniel F. McAuley,Michael Brown,Emilie Sanchez,Rachel Tattersall,Rachel Tattersall,Jessica J Manson +6 more
TL;DR: Re-analysis of data from a phase 3 randomised controlled trial of IL-1 blockade (anakinra) in sepsis, showed significant survival benefit in patients with hyperinflammation, without increased adverse events.
Journal ArticleDOI
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.
Daniel Wrapp,Nianshuang Wang,Kizzmekia S. Corbett,Jory A. Goldsmith,Ching-Lin Hsieh,Olubukola M. Abiona,Barney S. Graham,Jason S. McLellan +7 more
TL;DR: The authors show that this protein binds at least 10 times more tightly than the corresponding spike protein of severe acute respiratory syndrome (SARS)–CoV to their common host cell receptor, and test several published SARS-CoV RBD-specific monoclonal antibodies found that they do not have appreciable binding to 2019-nCoV S, suggesting that antibody cross-reactivity may be limited between the two RBDs.
Journal ArticleDOI
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Manli Wang,Ruiyuan Cao,Leike Zhang,Xing-Lou Yang,Jia Liu,Mingyue Xu,Zhengli Shi,Zhihong Hu,Wu Zhong,Gengfu Xiao +9 more
TL;DR: This study evaluated the antiviral efficiency of five FAD-approved drugs including ribavirin, penciclovir, nitazoxanide, nafamostat, chloroquine and two well-known broad-spectrum antiviral drugs remdesivir and favipiravir against a clinical isolate of 2019-nCoV in vitro.